elranatamab will enhance the stage or influence of fentanyl transdermal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Elranatamab causes cytokine launch syndrome (CRS) that may suppress exercise of CYP enzymes, causing elevated exposure of CYP substrates.brivaracetam and fentanyl transdermal each maximize sedation. Av